(Bloomberg) -- TA Associates is reviving plans to sell French cosmetic treatment company Laboratoires Vivacy, people familiar with the matter said.

The buyout firm is working with BNP Paribas SA and Rothschild & Co. on a potential divestment that could value Vivacy at about 1 billion euros ($1 billion), the people said. It has drawn interest from Asian competitors and other private equity firms, according to the people, who asked not to be identified discussing confidential information. 

Founded in 2007, Vivacy specializes in manufacturing injectable hyaluronic-acid dermal filler products, which are available in more than 75 countries, according to its website. TA Associates bought a majority stake in the company in 2019 for an undisclosed sum.

TA Associates sought to gauge potential interest in the business earlier in the year but nothing materialized, one of the people said.

Deliberations are at an early stage and there’s no certainty they’ll result in a sale, they said. Representatives for BNP Paribas, Rothschild and TA Associates declined to comment, while a spokesperson for Vivacy didn’t immediately provide comment.

(Updates with BNP Paribas response in last paragraph.)

©2022 Bloomberg L.P.